HROWL | Harrow Health, Inc. 8.625% Senior Notes due 2026 Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.33 - 25.45
52 Week Range	24.43 - 25.73
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	15,144
Average Volume	4,186
Shares Outstanding	36,846,040
Market Cap	935,561,811
Sector	Healthcare
Industry	Medical - Pharmaceuticals
IPO Date	2021-05-07

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	8.51%
Dividend Per Share	2.16
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	217
Country	USA
Website	HROWL

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

HROWL's peers: XOMAO, ATCOL, RWAYL, BWSN, BWNB, RILYT, RILYO, SPNT-PB, METCL, ARBKL, ATLCL, HNNAZ, RWAYZ, SNCRL, FOSLL, OXLCL, HROWM, SCCC

*Chart delayed

Analyzing fundamentals for HROWL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak. For more detailed analysis please see HROWL Fundamentals page.

Watching at HROWL technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on HROWL Technicals page.